CTTC’s Calmare remedial programme remarkable against distress associated with chemotherapy-induced perimetric neuropathy
Competitive Technologies, Inc. (OTCQB:CTTC) announced today the newsletter of the thorough results from a swotting that shows the well-to-do treatment of patients torment from grieve associated with chemotherapy-induced unessential neuropathy (CIPN) using CTTC’s Calmare® Soreness Psychotherapy Treatment. The article published in the Roll of Despair and Manifestation Directors (www.jpsmjournal.com), particularized the reflect on led nearby director investigator, Thomas J. Smith, M.D., Endowed Chairperson of Palliative Solicitude Into and Medical Gaffer of the Thomas Palliative Worry Item Virginia Commonwealth University’s Massey Cancer Center.
Calmare, which treats lasting neuropathic and oncologic ordeal, received FDA certification on the side of sales in the U.S. in 2009. In June 2009, clinical investigators at the VCU Massey Cancer Center began the opening U.S. unearned clinical survey, to specifically enquire into the faculty of CTTC’s Calmare ass effort cure treatment to fall off grief associated with CIPN.
Help-Medical.net finds at this phrases:
- xyntha patent fda
- mar531
- "A Hilarius pair of ducks"
- Akash Patnaik
- "Actogenix"+"litigation"
- PICCLe and olaparib
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
